open access

Vol 67, No 5 (2016)
Original papers
Published online: 2016-01-26
Submitted: 2015-09-17
Accepted: 2016-01-12
Get Citation

The impact of diabetes mellitus on the survival of patients with acromegaly

Chiou Wen-Ko, Chen Szu-Tah, Liu Feng-Hsuan, Chang Chen-Nen, Wang Ming-Hsu, Lin Jen-Der
DOI: 10.5603/EP.a2016.0031
·
Endokrynologia Polska 2016;67(5):501-506.

open access

Vol 67, No 5 (2016)
Original papers
Published online: 2016-01-26
Submitted: 2015-09-17
Accepted: 2016-01-12

Abstract

Introduction: An increased risk of mortality in patients with uncontrolled acromegaly has been reported in several studies. We aimed to assess the impact of co-morbidities on the survival of patients with acromegaly after long-term treatment and follow-up.

Material and methods: A retrospective analysis was performed for 285 patients with active acromegaly, who were admitted to the Chang Gung Memorial Hospital, Taiwan between 1978 and 2012. Of these patients, 106 (37.2%) were diagnosed with diabetes mellitus (DM). During the follow-up period, 21 cases of histological proved malignant in acromegalic patients, and DM with acromegaly had a higher incidence of malignancy (13.2% vs. 3.8%; p < 0.01). The 5-, 10-, and 20-year survival rates were 93.1%, 86.9%, and 84.7% for the DM group, respectively, and 96.5%, 96.5%, and 96.5% for the non-DM group, respectively. After a mean follow-up of 15.1 ± 0.6 years, age, DM, coronary heart disease, and malignancy were found to be significant factors of mortality. Control of growth hormone and IGF-1 levels also conferred a marginal survival benefit.

Conclusions: DM and malignancy significantly influence the survival of patients with acromegaly; thus, these patients need close follow-up and appropriate therapy. (Endokrynol Pol 2016; 67 (5): 501–506)

Abstract

Introduction: An increased risk of mortality in patients with uncontrolled acromegaly has been reported in several studies. We aimed to assess the impact of co-morbidities on the survival of patients with acromegaly after long-term treatment and follow-up.

Material and methods: A retrospective analysis was performed for 285 patients with active acromegaly, who were admitted to the Chang Gung Memorial Hospital, Taiwan between 1978 and 2012. Of these patients, 106 (37.2%) were diagnosed with diabetes mellitus (DM). During the follow-up period, 21 cases of histological proved malignant in acromegalic patients, and DM with acromegaly had a higher incidence of malignancy (13.2% vs. 3.8%; p < 0.01). The 5-, 10-, and 20-year survival rates were 93.1%, 86.9%, and 84.7% for the DM group, respectively, and 96.5%, 96.5%, and 96.5% for the non-DM group, respectively. After a mean follow-up of 15.1 ± 0.6 years, age, DM, coronary heart disease, and malignancy were found to be significant factors of mortality. Control of growth hormone and IGF-1 levels also conferred a marginal survival benefit.

Conclusions: DM and malignancy significantly influence the survival of patients with acromegaly; thus, these patients need close follow-up and appropriate therapy. (Endokrynol Pol 2016; 67 (5): 501–506)

Get Citation

Keywords

co-morbidities; malignancy; IGF-1

About this article
Title

The impact of diabetes mellitus on the survival of patients with acromegaly

Journal

Endokrynologia Polska

Issue

Vol 67, No 5 (2016)

Pages

501-506

Published online

2016-01-26

DOI

10.5603/EP.a2016.0031

Bibliographic record

Endokrynologia Polska 2016;67(5):501-506.

Keywords

co-morbidities
malignancy
IGF-1

Authors

Chiou Wen-Ko
Chen Szu-Tah
Liu Feng-Hsuan
Chang Chen-Nen
Wang Ming-Hsu
Lin Jen-Der

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl